Iván Márquez‐Rodas

29.5k citations
121 papers · 4.1k · 2 hit papers · h-index 25

Impact in

  • Oncology top 0.5%
    • Cancer Immunotherapy and Biomarkers
    • CAR-T cell therapy research
    • Cutaneous Melanoma Detection and Management
  • Immunology top 2%
    • Immunotherapy and Immune Responses
    • Immune Cell Function and Interaction
    • Immune cells in cancer

Papers in

    • Cancer Immunotherapy and Biomarkers 39
    • CAR-T cell therapy research 32
    • Cutaneous Melanoma Detection and Management 19
    • Melanoma and MAPK Pathways 31

Iván Márquez‐Rodas

111 papers receiving 4.1k citations

Iván Márquez‐Rodas's Hit Papers

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial 2018 · 1.0k citations
1.0k0+3+6Years since publication2505007501000

Peers

Iván Márquez‐Rodas
Comparison fields: 5 of 107
  • Oncology 2.6k
  • Immunology 1.0k
  • Cancer Research 307
  • Pulmonary and Respiratory Medicine 608
  • Genetics 168
Replace Hussein A. Tawbi with:
Hussein A. Tawbi United States
Luis de la Cruz‐Merino Spain
Geoffrey T. Gibney United States
Michele Guida Italy
Ronan J. Kelly United States
Miles C. Andrews Australia
Paul Frankel United States
James M. Cleary United States
Alejandro D. Ricart United States
Vasiliki Pelekanou United States
Iván Márquez‐Rodas relative to Hussein A. Tawbi United States Hussein A. Tawbi's profile →
Citations per field
00.5×1.6×
Hussein A. Tawbi · 1×
Citations per year

Countries citing papers authored by Iván Márquez‐Rodas

Since Specialization
Citations

This map shows the geographic impact of Iván Márquez‐Rodas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Iván Márquez‐Rodas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Iván Márquez‐Rodas more than expected).

Fields of papers citing papers by Iván Márquez‐Rodas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Iván Márquez‐Rodas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Iván Márquez‐Rodas. The network helps show where Iván Márquez‐Rodas may publish in the future.

Co-authors

The 25 scholars most cited alongside Iván Márquez‐Rodas, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Iván Márquez‐Rodas Line = papers co-authored together Iván Márquez‐Rodas links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 121 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
Hit paper breakdown →
20181033
2
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
Hit paper breakdown →
2017490
3 2019329
4 2019253
5 2018200
6 2017127
7 2005104
8 2019104
9 2021103
10 201585
11 201271
12 201967
13 201864
14 201560
15 201655
16 202254
17 201853
18 202042
19 201442
20 201441

About Iván Márquez‐Rodas

Iván Márquez‐Rodas is a scholar working on Oncology, Molecular Biology, Immunology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 121 papers that have together received 4.1k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (39 papers), CAR-T cell therapy research (32 papers), Melanoma and MAPK Pathways (31 papers), Cutaneous Melanoma Detection and Management (19 papers), Immunotherapy and Immune Responses (13 papers), BRCA gene mutations in cancer (8 papers), Cancer-related molecular mechanisms research (5 papers) and Immune cells in cancer (4 papers). The work is most often cited by research in Oncology (2.6k citations), Immunology (1.0k citations), Cancer Research (307 citations), Pulmonary and Respiratory Medicine (608 citations) and Genetics (168 citations). Iván Márquez‐Rodas has collaborated with scholars based in Spain, United States and United Kingdom. Frequent co-authors include Vanna Chiarion‐Sileni, Dirk Schadendorf, James Larkin, David Hogg, Michael Smylie, Piotr Rutkowski, F. Stephen Hodi, Reinhard Dummer, René González and Jedd D. Wolchok. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Clinical & Translational Oncology, Breast Cancer Research and Treatment and Regulatory Peptides.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact